The clinical benefit of adding platinum to adjuvant chemotherapy for patients with triple-negative breast cancer (TNBC) has not been well investigated, although it was associated an improved response rate in neoadjuvant setting. We retrospectively analyzed the time to tumor progression (TTP) and overall survival (OS) of patients with resected stage I-III TNBC who were treated with or without cisplatin-containing chemotherapy (CisCT or noCisCT) during 2004 and 2010. Of 129 patients, 25 received CisCT. In univariate analysis, the mean TTP for CisCT and noCisCT was 4.42 and 5.88 years, respectively (P = .004). The mean OS for CisCT and noCisCT was 6.76 and 9.63 years, respectively (P = .24). After adjusting for other clinicopathologic factors, only clinical stage II/III disease was independently associated with worse OS. The adjusted hazard ratio for CisCT was 1.48 (P = .46) and was not statistically significant. In this small retrospective study, adding cisplatin to adjuvant chemotherapy for early TNBC with unknown BRCA mutation status did not benefit OS.

中文翻译：

---

对于患有未知BRCA突变状态的三阴性乳腺癌患者，将顺铂纳入辅助化疗的单一机构经验。

虽然三联阴性乳腺癌（TNBC）患者在辅助化疗中添加铂的临床获益尚无很好的研究，尽管它与新辅助治疗中提高的缓解率相关。我们回顾性分析了2004年至2010年间接受或不接受含顺铂化疗（CisCT或noCisCT）的I-III期TNBC切除患者的肿瘤进展时间（TTP）和总生存期（OS）。在129例患者中， 25收到了CisCT。在单变量分析中，CisCT和noCisCT的平均TTP分别为4.42年和5.88年（P = .004）。CisCT和noCisCT的平均OS分别为6.76和9.63岁（P = 0.24）。在调整了其他临床病理因素后，只有II / III期临床疾病与OS恶化独立相关。调整后的CisCT危险比为1.48（P = 0.46），且无统计学意义。在这项小型回顾性研究中，将顺铂添加到BRCA突变状态未知的早期TNBC的辅助化疗中不会使OS受益。